The 9M FY25 registers Rs 9200 crore revenue

Mankind Pharma announced its financial results for the third quarter and nine months ended December 31, 2024. The information mentioned in this release is based on consolidated financial statements.

Rajeev Juneja – Vice Chairman and Managing Director, Mankind Pharma said, "We achieved a healthy revenue growth of 24 per cent YoY with strong adjusted EBITDA margin of 27.7 per cent in Q3FY25, driven by continued outperformance in Chronic, strong recovery in OTC and consolidation of BSV. 30 per cent YoY revenue growth in OTC business supported by strategic initiatives undertaken last year. The integration of BSV is on track, with a focus on mandate brands, improving productivity and adopting best practices to ensure long-term sustainable growth. 2024 has been a transformative year - now having multiple building blocks – steady base business, fast-growing speciality chronic segment, high potential OTC business, and high-entry barrier super speciality portfolio of BSV."